US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
AU4990696A
(en)
*
|
1995-02-24 |
1996-09-11 |
Nanosystems L.L.C. |
Aerosols containing nanoparticle dispersions
|
US20050267302A1
(en)
*
|
1995-12-11 |
2005-12-01 |
G.D. Searle & Co. |
Eplerenone crystalline form exhibiting enhanced dissolution rate
|
ZA9711732B
(en)
*
|
1996-12-31 |
1998-12-28 |
Quadrant Holdings Cambridge |
Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
UA72189C2
(en)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
HU230454B1
(en)
*
|
1998-11-02 |
2016-07-28 |
Alkermes Pharma Ireland Limited |
Multiparticulate modified release composition of methylphenidate
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US20040141925A1
(en)
*
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US20020054914A1
(en)
*
|
1999-02-03 |
2002-05-09 |
Tulin Morcol |
Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
|
ATE276199T1
(en)
|
1999-02-03 |
2004-10-15 |
Biosante Pharmaceuticals Inc |
METHODS FOR PRODUCING THERAPEUTIC CALCIUM PHOSPHATE PARTICLES
|
US20040258763A1
(en)
*
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
US6270806B1
(en)
|
1999-03-03 |
2001-08-07 |
Elan Pharma International Limited |
Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US7919119B2
(en)
*
|
1999-05-27 |
2011-04-05 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US6610317B2
(en)
|
1999-05-27 |
2003-08-26 |
Acusphere, Inc. |
Porous paclitaxel matrices and methods of manufacture thereof
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20030096798A1
(en)
*
|
1999-11-09 |
2003-05-22 |
Williams Gordon H. |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
US20030203884A1
(en)
*
|
1999-11-09 |
2003-10-30 |
Pharmacia Corporation |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
CA2362845A1
(en)
*
|
1999-12-08 |
2001-06-14 |
Pharmacia Corporation |
Eplerenone crystalline form
|
DK1175214T3
(en)
*
|
1999-12-08 |
2006-07-17 |
Pharmacia Corp |
Cyclooxygenase-2 inhibitor compositions with rapid onset of therapeutic effect
|
US20030083493A1
(en)
*
|
1999-12-08 |
2003-05-01 |
Barton Kathleen P. |
Eplerenone drug substance having high phase purity
|
GB0009773D0
(en)
|
2000-04-19 |
2000-06-07 |
Univ Cardiff |
Particulate composition
|
DK1280520T4
(en)
*
|
2000-05-10 |
2018-06-25 |
Novartis Ag |
Phospholipid based powders for drug delivery
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
MY120279A
(en)
|
2000-05-26 |
2005-09-30 |
Pharmacia Corp |
Use of a celecoxib composition for fast pain relief
|
EP1299123A2
(en)
*
|
2000-07-13 |
2003-04-09 |
Pharmacia Corporation |
Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
|
PE20020146A1
(en)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
|
ES2265437T3
(en)
*
|
2000-07-27 |
2007-02-16 |
Pharmacia Corporation |
EPOXI-STEROID ANTAGONIST COMBINATION THERAPY OF ALDOSTERONE AND BETA-ADRENERGIC ANTAGONIST FOR TREATMENT OF CONGESTIVE CARDIAC INSUFFICIENCY.
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
ES2251505T3
(en)
*
|
2000-08-28 |
2006-05-01 |
Pharmacia Corporation |
USE OF AN ALGOSTERONE RECEIVER ANTAGONIST TO IMPROVE COGNOSCITIVE FUNCTION.
|
US20060177416A1
(en)
*
|
2003-10-14 |
2006-08-10 |
Medivas, Llc |
Polymer particle delivery compositions and methods of use
|
DE60137943D1
(en)
|
2000-08-31 |
2009-04-23 |
Jagotec Ag |
GROUND PARTICLES
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US20040081627A1
(en)
*
|
2000-10-09 |
2004-04-29 |
Jinks Phillip A |
Medicinal aerosol formulations
|
EP1324749B1
(en)
*
|
2000-10-09 |
2006-03-15 |
3M Innovative Properties Company |
Medicinal aerosol formulations
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
US20030087308A1
(en)
*
|
2001-06-22 |
2003-05-08 |
Elan Pharma International Limited |
Method for high through put screening using a small scale mill or microfluidics
|
US20030220310A1
(en)
*
|
2001-07-27 |
2003-11-27 |
Schuh Joseph R. |
Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
|
US20030185892A1
(en)
*
|
2001-08-17 |
2003-10-02 |
Bell Steve J. D. |
Intraocular delivery compositions and methods
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
WO2003024425A1
(en)
*
|
2001-09-19 |
2003-03-27 |
Elan Pharma International, Ltd. |
Nanoparticulate insulin formulations
|
JP2005529060A
(en)
*
|
2001-09-25 |
2005-09-29 |
ファルマシア コーポレイション |
Solid form of N- (2-hydroxyacetyl) -5- (4-piperidyl) -4- (4-pyrimidinyl) -3- (4-chlorophenyl) pyrazole
|
AU2002334939A1
(en)
*
|
2001-10-12 |
2003-04-22 |
Eugene R. Cooper |
Compositions having a combination of particles for immediate release and for controlled release
|
WO2003053411A1
(en)
*
|
2001-12-19 |
2003-07-03 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
JP4598399B2
(en)
*
|
2002-02-04 |
2010-12-15 |
エラン ファーマ インターナショナル,リミティド |
Nanoparticle composition with lysozyme as surface stabilizer
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
CA2479735C
(en)
*
|
2002-03-20 |
2011-05-17 |
Elan Pharma International Ltd. |
Fast dissolving dosage forms having reduced friability
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
ATE343376T1
(en)
*
|
2002-03-20 |
2006-11-15 |
Elan Pharma Int Ltd |
NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
|
US7101576B2
(en)
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
DK1494649T3
(en)
|
2002-04-12 |
2012-04-10 |
Alkermes Pharma Ireland Ltd |
Nanoparticle-MEGESTROLFORMULERINGER
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
CA2484637A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Elan Pharma International Ltd. |
Nanoparticulate nystatin formulations
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
AU2003241477A1
(en)
*
|
2002-06-10 |
2003-12-22 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
AU2003261167A1
(en)
|
2002-07-16 |
2004-02-02 |
Elan Pharma International, Ltd |
Liquid dosage compositions of stable nanoparticulate active agents
|
US20030017208A1
(en)
*
|
2002-07-19 |
2003-01-23 |
Francis Ignatious |
Electrospun pharmaceutical compositions
|
UY27939A1
(en)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
COMPOUNDS
|
EP1556091A1
(en)
*
|
2002-10-04 |
2005-07-27 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
ES2365012T3
(en)
*
|
2002-11-12 |
2011-09-20 |
Elan Pharma International Limited |
SOLID PHARMACEUTICAL FORMS OF QUICK DISINTEGRATION THAT ARE NOT RELIABLE AND UNDERSTANDING PULULANO.
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
US20040173696A1
(en)
*
|
2002-12-17 |
2004-09-09 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
CA2513064C
(en)
*
|
2003-01-31 |
2009-11-10 |
Elan Pharma International, Ltd. |
Nanoparticulate topiramate formulations
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
US8512727B2
(en)
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
ATE406364T1
(en)
*
|
2003-03-07 |
2008-09-15 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
|
MXPA05009501A
(en)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia.
|
EP1625334B9
(en)
|
2003-05-21 |
2012-07-25 |
Alexza Pharmaceuticals, Inc. |
Percussively ignited self-contained heating unit
|
WO2004105809A1
(en)
*
|
2003-05-22 |
2004-12-09 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
EP1651189B1
(en)
*
|
2003-08-08 |
2008-12-03 |
Elan Pharma International Limited |
Novel metaxalone compositions
|
ES2281021T3
(en)
*
|
2003-10-15 |
2007-09-16 |
Pari Pharma Gmbh |
LIQUID FORMULATION CONTAINING TOBRAMYCIN.
|
ES2366646T3
(en)
*
|
2003-11-05 |
2011-10-24 |
Elan Pharma International Limited |
COMPOSITIONS IN THE FORM OF NANOPARTICLES THAT HAVE A PEPTIDE AS A SURFACE STABILIZER.
|
ES2344303T3
(en)
*
|
2004-02-13 |
2010-08-24 |
Nod Pharmaceuticals, Inc. |
PARTICLES THAT INCLUDE A NUCLEO OF CALCICO PHOSPHATE NANOPARTICLES, A BIOMOLECULA AND A BILIAR ACID, PRODUCTION METHODS AND THERAPEUTIC USE OF THE SAME.
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
EP1811941A4
(en)
|
2004-11-01 |
2008-09-10 |
Biosante Pharmaceuticals Inc |
Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
|
EP1827374B1
(en)
*
|
2004-11-16 |
2014-11-05 |
Alkermes Pharma Ireland Limited |
Injectable nanoparticulate olanzapine formulations
|
CN1301747C
(en)
*
|
2004-11-30 |
2007-02-28 |
深圳市海王英特龙生物技术股份有限公司 |
Protein medicine microcapsule and inhalational aerosol thereof
|
UA89513C2
(en)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Nanoparticulate raloxifene hydrochloride composition
|
EP1835889A1
(en)
*
|
2004-12-15 |
2007-09-26 |
Elan Pharma International Limited |
Nanoparticulate tacrolimus formulations
|
US20060159767A1
(en)
*
|
2004-12-22 |
2006-07-20 |
Elan Pharma International Limited |
Nanoparticulate bicalutamide formulations
|
BRPI0606434A2
(en)
*
|
2005-01-06 |
2009-06-30 |
Elan Pharma Int Ltd |
nanoparticulate candesartan formulations
|
US20060198896A1
(en)
*
|
2005-02-15 |
2006-09-07 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
EP1855651A4
(en)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
Nanoparticulate compositions of heterocyclic amide derivatives
|
WO2006099121A2
(en)
*
|
2005-03-10 |
2006-09-21 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
|
WO2006099591A1
(en)
*
|
2005-03-16 |
2006-09-21 |
Elan Pharma International Limited |
Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
|
NZ561666A
(en)
*
|
2005-03-17 |
2010-05-28 |
Elan Pharma Int Ltd |
Nanoparticulate biphosphonate compositions
|
EA200702049A1
(en)
*
|
2005-03-23 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
COMPOSITIONS OF CORTICOSTEROID NANOPARTICLES WITH ANTIGISTAMINS
|
US20060246141A1
(en)
*
|
2005-04-12 |
2006-11-02 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
JP2008535921A
(en)
|
2005-04-12 |
2008-09-04 |
エラン・ファルマ・インターナショナル・リミテッド |
Nanoparticles containing cyclosporine and controlled release compositions
|
WO2006110811A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
US20110064803A1
(en)
*
|
2005-05-10 |
2011-03-17 |
Elan Pharma International Limited. |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
AU2006336417A1
(en)
*
|
2005-05-10 |
2007-08-02 |
Elan Pharma International, Limited |
Nanoparticulate clopidogrel formulations
|
US20100028439A1
(en)
*
|
2005-05-23 |
2010-02-04 |
Elan Pharma International Limited |
Nanoparticulate stabilized anti-hypertensive compositions
|
US20070042049A1
(en)
*
|
2005-06-03 |
2007-02-22 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
US20060275372A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Elan Pharma International Limited |
Nanoparticulate imatinib mesylate formulations
|
KR20080017065A
(en)
*
|
2005-06-03 |
2008-02-25 |
엘란 파마 인터내셔널 리미티드 |
Nanoparticulate acetaminophen formulations
|
CA2612994A1
(en)
|
2005-06-08 |
2006-12-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cefditoren
|
CA2611475A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Elan Pharma International, Limited |
Nanoparticulate ebastine formulations
|
KR20080016952A
(en)
*
|
2005-06-13 |
2008-02-22 |
엘란 파마 인터내셔널 리미티드 |
Nanoparticulate clopidogrel and aspirin combination formulations
|
CA2612384A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Elan Pharma International, Limited |
Nanoparticulate azelnidipine formulations
|
CA2614409C
(en)
*
|
2005-07-07 |
2014-05-20 |
Nanotherapeutics, Inc |
Process for milling and preparing powders and compositions produced thereby
|
EP1904041A2
(en)
*
|
2005-07-07 |
2008-04-02 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
JP2009507925A
(en)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
Nanoparticle tadalafil formulation
|
WO2007035348A2
(en)
|
2005-09-15 |
2007-03-29 |
Elan Pharma International, Limited |
Nanoparticulate aripiprazole formulations
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
JP2009538927A
(en)
*
|
2006-05-30 |
2009-11-12 |
エラン ファーマ インターナショナル,リミティド |
Nanoparticulate posaconazole formulation
|
JP2009543797A
(en)
*
|
2006-07-10 |
2009-12-10 |
エラン ファーマ インターナショナル,リミティド |
Nanoparticulate sorafenib formulation
|
TW200820992A
(en)
*
|
2006-07-12 |
2008-05-16 |
Elan Corp Plc |
Nanoparticulate formulations of modafinil
|
CL2007002689A1
(en)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
COMPOUNDS DERIVED FROM PIPERIDIN-1-CARBOXAMIDA, INHIBITORS OF THE RENINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERTENSION, CARDIAC INSUFFICIENCY, CARDIAC FIBROSIS, AMONG OTHERS.
|
EP2121088B1
(en)
|
2007-03-09 |
2016-07-13 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
JP2011520779A
(en)
*
|
2008-03-21 |
2011-07-21 |
エラン・ファルマ・インターナショナル・リミテッド |
Compositions and methods of use for site-specific delivery of imatinib
|
US7828996B1
(en)
*
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
CN102458380A
(en)
*
|
2009-04-24 |
2012-05-16 |
先灵公司 |
Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
|
FR2945950A1
(en)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
ANTICANCER NANOPARTICLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME
|
JP6072539B2
(en)
|
2009-05-27 |
2017-02-01 |
アルカーメス ファーマ アイルランド リミテッド |
Reduction of flaky aggregation in nanoparticulate active agent compositions
|
AR077692A1
(en)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
SALTS OF 2 - ((R) - (3-CHLOROPHENYL) ((R) -1 - ((S) -2- (METHYLAMINE) -3 - ((R) -TETRAHYDRO-2H-PIRAN-3-IL) PROPILCARBAMOIL ) PIPERIDIN -3-IL) METOXI) METHYL ETILCARBAMATE
|
US20110236769A1
(en)
*
|
2010-03-23 |
2011-09-29 |
Xing Xie |
Three dimensional electrodes useful for microbial fuel cells
|
WO2012038374A2
(en)
*
|
2010-09-20 |
2012-03-29 |
L'oreal |
Aqueous cosmetic composition comprising alkylcellulose
|
JP6166721B2
(en)
|
2011-07-22 |
2017-07-19 |
ケモセントリックス, インコーポレイテッド |
4-tert-Butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide sodium salt polymorph
|
HUE032747T2
(en)
|
2011-07-22 |
2017-10-30 |
Chemocentryx Inc |
A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
|
SG2014011886A
(en)
|
2011-09-01 |
2014-05-29 |
Glaxo Group Ltd |
Novel crystal form
|
SG11201610709UA
(en)
|
2014-06-25 |
2017-01-27 |
Glaxosmithkline Ip Dev Ltd |
Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
|
BR112017004673A2
(en)
|
2014-09-08 |
2017-12-05 |
Glaxosmithkline Ip Dev Ltd |
2- (4- (4-Ethoxy-6-oxo-1,6-dihydropyridin-3-yl) -2-fluorophenyl) -n- (5- (1,1,1-trifluoro-2-methylpropan) crystalline forms -2-yl) isoxazol-3-yl) acetamide
|
CN107709344B
(en)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
Nucleoside analogues for the treatment of flaviviridae and cancer
|
TWI773641B
(en)
*
|
2015-05-08 |
2022-08-11 |
日商活效製藥股份有限公司 |
Aqueous suspension containing nano particles of glucocorticoids
|
JP6828040B2
(en)
|
2015-12-21 |
2021-02-10 |
ロレアル |
Compositions containing alkyl cellulose and incompatible hydrocarbons and silicone oils and methods using them
|
CA3087192A1
(en)
|
2017-12-27 |
2019-07-04 |
Raymond F. Schinazi |
Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
|